A phase II open-label trial of apomine (SR-45023A) in patients with refractory melanoma

Investigational New Drugs - Tập 24 - Trang 89-94 - 2006
Karl D. Lewis1, John A. Thompson2, Jeffrey S. Weber3, William A Robinson1, Steven O'Day4, Jose Lutzky5, Sewa S. Legha6, Simon Floret7, Francis Ruvuna8, Rene Gonzalez1
1University of Colorado, Cancer Center, Aurora
2University of Washington, Seattle
3University of Southern California, Norris Cancer Center, Los Angeles
4Cancer Institute Medical Group, Santa Monica
5Mount Sinai Comprehensive Cancer Center
6Saint Luke's Episcopal Hospital, Houston
7ILEX Oncology Research Sarl—Geneva, Versoix/Geneva, Switzerland
8ILEX Products, Inc, San Antonio

Tóm tắt

Metastatic melanoma continues to be a very difficult disease to treat. Options are limited and often have very little impact on the course of the disease. The objective of the current study was to evaluate the efficacy and safety of continuously administered Apomine (SR-45023A), a novel bisphosphonate, in patients with previously treated metastatic malignant melanoma. Adult patients with previously treated metastatic melanoma received Apomine 100 mg orally, twice daily (total dose 200 mg per day) continuously for 28 days (defined as a cycle). Treatment was continued until disease progression or unacceptable toxicity. A total of 42 patients received at least one dose of Apomine. Stable disease was achieved in 2 patients (5%). No complete or partial responses were observed. Progression free survival of at least 16 weeks was observed in 6 patients (14%). The median overall survival was 6.1 months (95% CI, 4.9–9.4 months). Time to treatment failure was 1.7 months (95% CI, 1.6–1.8 months) with Apomine therapy. By cycle 2, Apomine concentrations reached steady-state. Apomine was well tolerated with only 37% of patients experiencing any drug-related event. Abdominal pain was the most frequent adverse event occurring in 26% of patients. In conclusion, Apomine, at the current dose studied, failed to produce a 30% progression free survival rate at 16 weeks considered to be a meaningful benefit for further development.

Tài liệu tham khảo

Jemal A, Tiwari RC, Murray T, Ghafoor A, Samuels A, Ward E, Feuer Thun MJ: Cancer statistics, 2004. CA Cancer J Clin 54:8–29, 2004 Flach J, Antoni I, Villemin P, Bentzen CL, Niesor EJ: The mevalonate/isoprenoid pathway inhibitor apomine (SR-45023A) is antiproliferative and induces apoptosis similar to farnesol. Biochem Biophys Res Commun 270:240–246, 2000 Lowe LC, Senaratne SG, Colston KW: Induction of apoptosis in breast cancer cells by apomine is mediated by caspase and p38 mitogen activated protein kinase activation. Biochem Biophys Res Commun 329:772–779, 2005 Niesor EJ, Flach J, Lopes-Antoni I, Perez A, Bentzen CL: The nuclear receptors FXR and LXRalpha: Potential targets for the development of drugs affecting lipid metabolism and neoplastic diseases. Curr Pharm Des 7:231–259, 2001 Powell MB, Alberts DS, Lluria-Prevatt M, Carrier A, Lopez AM, Hersh E, Kinsey A, Smith S, Niesor EJ, Bentzen CL: Preclinical and clinical activity of Apomine, a novel bisphosphonate ester, in the prevention and treatment of melanoma. Abstract 4992 Proc Amer Assoc Cancer Res 43:1007, 2002 Soengas MS, Lowe SW: Apoptosis and melanoma chemoresistance. Oncogene 22:3138–3151, 2003 Ivanov VN, Bhoumik A, Ronai Z: Death receptors and melanoma resistance to apoptosis. Oncogene 22:3152–3161, 2003 Hussein MR, Haemel AK, Wook GS: Apoptosis and melanoma: Molecular mechanisms. J Pathol 199:275–288, 2003 Bonate PL, Floret S, Bentzen C: Population pharmacokinetics of apomine: A meta-analysis in cancer patients and healthy males. Br J Clin Pharmacol 58:142–155, 2004 Middleton MR, Grob JJ, Aaronson N, Fierlbeck G, Tilgen W, Seiter S, Gore M, Aamdal S, Cebon J, Coates A, Dreno B, Henz M, Schadendorf D, Dapp A, Weiss J, Fraass U, Statkevich P, Muller M, Thatcher N: Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. J Clin Oncol 18:158–166, 2000 Eisman JA, Rizzoli R, Roman-Ivorra J, Lipschitz S, Verbruggen N, Gaines KA, Melton ME: Upper gastrointestinal and overall tolerability of alendronate once weekly in patients with osteoporosis: Results of a randomized, double-blind, placebo-controlled study. Curr Med Res Opin 20:699–705, 2004